PIMAVANSERIN: HITTING THE SPOT IN HALLUCINATION AND DELUSION OF PARKINSON’S DISEASE

Dick B. S. Brashier, Prashant Mishra*, Htet Wai Moe, Kedar G. Bandekar and Neha Akhoon

ABSTRACT

Parkinson’s disease psychosis (PDP) is a vivid suffering with high morbidity and mortality rate in Parkinson’s disease patients. After a long era of precautious atypical antipsychotic treatments, the first and safer drug Pimavanserin was recently approved by FDA. Pimavanserin is a highly selective 5-HT2A receptor inverse agonist. It showed high level of safety and tolerability with effective symptom control of Parkinson’s disease psychosis. The most prominent benefit of Pimavanserin is avoidance of motoric and non-motoric side effects. Pimavanserin brings meaningful hopes to Parkinson’s disease psychotic patients but further voluminous research needs to be engaged in the treatment of PDP.

Keywords: Parkinson’s disease psychosis, Pimavanserin, 5-HT2A